Published in Trends Cardiovasc Med on February 01, 2007
Genetics of Cardiovascular and Neuromuscular Disease | NCT00138931
Mechanotransduction gone awry. Nat Rev Mol Cell Biol (2009) 4.00
The interaction between nesprins and sun proteins at the nuclear envelope is critical for force transmission between the nucleus and cytoskeleton. J Biol Chem (2011) 2.21
A zyxin-mediated mechanism for actin stress fiber maintenance and repair. Dev Cell (2010) 1.62
Contemporary cardiac issues in Duchenne muscular dystrophy. Working Group of the National Heart, Lung, and Blood Institute in collaboration with Parent Project Muscular Dystrophy. Circulation (2015) 1.55
Engineered electrical conduction tract restores conduction in complete heart block: from in vitro to in vivo proof of concept. J Am Coll Cardiol (2014) 1.43
DOT1L regulates dystrophin expression and is critical for cardiac function. Genes Dev (2011) 1.25
Worsening of cardiomyopathy using deflazacort in an animal model rescued by gene therapy. PLoS One (2011) 1.05
Myogenic Akt signaling upregulates the utrophin-glycoprotein complex and promotes sarcolemma stability in muscular dystrophy. Hum Mol Genet (2008) 1.02
Deregulated protein kinase A signaling and myospryn expression in muscular dystrophy. J Biol Chem (2008) 0.97
Progress in gene therapy of dystrophic heart disease. Gene Ther (2012) 0.96
Leaky ryanodine receptors in β-sarcoglycan deficient mice: a potential common defect in muscular dystrophy. Skelet Muscle (2012) 0.95
Exclusive skeletal muscle correction does not modulate dystrophic heart disease in the aged mdx model of Duchenne cardiomyopathy. Hum Mol Genet (2013) 0.94
Delta-sarcoglycan gene therapy halts progression of cardiac dysfunction, improves respiratory failure, and prolongs life in myopathic hamsters. Circ Heart Fail (2010) 0.93
Mechanotransduction at the basis of endothelial barrier function. Tissue Barriers (2013) 0.93
Serial examination of an inducible and reversible dilated cardiomyopathy in individual adult Drosophila. PLoS One (2009) 0.90
S151A δ-sarcoglycan mutation causes a mild phenotype of cardiomyopathy in mice. Eur J Hum Genet (2013) 0.86
Calpain inhibition preserves talin and attenuates right heart failure in acute pulmonary hypertension. Am J Respir Cell Mol Biol (2012) 0.85
Fluorescence-based force/tension sensors: a novel tool to visualize mechanical forces in structural proteins in live cells. Antioxid Redox Signal (2014) 0.85
Sarcospan: a small protein with large potential for Duchenne muscular dystrophy. Skelet Muscle (2013) 0.85
Absence of Dystrophin Disrupts Skeletal Muscle Signaling: Roles of Ca2+, Reactive Oxygen Species, and Nitric Oxide in the Development of Muscular Dystrophy. Physiol Rev (2016) 0.85
Modeling dilated cardiomyopathies in Drosophila. Trends Cardiovasc Med (2012) 0.84
Transcriptional networks regulating the costamere, sarcomere, and other cytoskeletal structures in striated muscle. Cell Mol Life Sci (2013) 0.83
Genetic background of Prop1(df) mutants provides remarkable protection against hypothyroidism-induced hearing impairment. J Assoc Res Otolaryngol (2011) 0.82
Does delta-sarcoglycan-associated autosomal-dominant cardiomyopathy exist? Eur J Hum Genet (2009) 0.80
Myoclonus dystonia and muscular dystrophy: ɛ-sarcoglycan is part of the dystrophin-associated protein complex in brain. Mov Disord (2016) 0.79
Chronic oral administration of Ang-(1-7) improves skeletal muscle, autonomic and locomotor phenotypes in muscular dystrophy. Clin Sci (Lond) (2014) 0.79
Genome-wide Mechanosensitive MicroRNA (MechanomiR) Screen Uncovers Dysregulation of Their Regulatory Networks in the mdm Mouse Model of Muscular Dystrophy. J Biol Chem (2015) 0.77
Isoproterenol induces primary loss of dystrophin in rat hearts: correlation with myocardial injury. Int J Exp Pathol (2008) 0.76
Myocardial Contractile Dysfunction Is Present without Histopathology in a Mouse Model of Limb-Girdle Muscular Dystrophy-2F and Is Prevented after Claudin-5 Virotherapy. Front Physiol (2016) 0.75
Spontaneous coronary vasospasm in KATP mutant mice arises from a smooth muscle-extrinsic process. Circ Res (2006) 2.64
Bacillus anthracis edema toxin causes extensive tissue lesions and rapid lethality in mice. Am J Pathol (2005) 2.45
The dystrophin glycoprotein complex: signaling strength and integrity for the sarcolemma. Circ Res (2004) 2.29
Nesprin-1alpha self-associates and binds directly to emerin and lamin A in vitro. FEBS Lett (2002) 2.24
Episodic coronary artery vasospasm and hypertension develop in the absence of Sur2 K(ATP) channels. J Clin Invest (2002) 2.11
Mechanisms of muscle degeneration, regeneration, and repair in the muscular dystrophies. Annu Rev Physiol (2009) 2.03
Myne-1, a spectrin repeat transmembrane protein of the myocyte inner nuclear membrane, interacts with lamin A/C. J Cell Sci (2002) 2.02
Population-based variation in cardiomyopathy genes. Circ Cardiovasc Genet (2012) 2.00
Normal myoblast fusion requires myoferlin. Development (2005) 1.97
Disruption of nesprin-1 produces an Emery Dreifuss muscular dystrophy-like phenotype in mice. Hum Mol Genet (2008) 1.83
Familial dilated cardiomyopathy caused by an alpha-tropomyosin mutation: the distinctive natural history of sarcomeric dilated cardiomyopathy. J Am Coll Cardiol (2010) 1.83
The genetics of dilated cardiomyopathy. Curr Opin Cardiol (2010) 1.76
Calcium-sensitive phospholipid binding properties of normal and mutant ferlin C2 domains. J Biol Chem (2002) 1.73
Latent TGF-beta-binding protein 4 modifies muscular dystrophy in mice. J Clin Invest (2009) 1.67
Age-dependent effect of myostatin blockade on disease severity in a murine model of limb-girdle muscular dystrophy. Am J Pathol (2006) 1.64
LTBP4 genotype predicts age of ambulatory loss in Duchenne muscular dystrophy. Ann Neurol (2013) 1.63
Functional nitric oxide synthase mislocalization in cardiomyopathy. J Mol Cell Cardiol (2004) 1.58
Nesprin-1 mutations in human and murine cardiomyopathy. J Mol Cell Cardiol (2009) 1.48
The endocytic recycling protein EHD2 interacts with myoferlin to regulate myoblast fusion. J Biol Chem (2008) 1.45
S100A12 mediates aortic wall remodeling and aortic aneurysm. Circ Res (2009) 1.36
Genetic background influences muscular dystrophy. Neuromuscul Disord (2005) 1.34
Nesprin-1alpha contributes to the targeting of mAKAP to the cardiac myocyte nuclear envelope. Exp Cell Res (2005) 1.34
S100A12 in vascular smooth muscle accelerates vascular calcification in apolipoprotein E-null mice by activating an osteogenic gene regulatory program. Arterioscler Thromb Vasc Biol (2010) 1.32
Reduced life span with heart and muscle dysfunction in Drosophila sarcoglycan mutants. Hum Mol Genet (2007) 1.28
Transplanted hematopoietic stem cells demonstrate impaired sarcoglycan expression after engraftment into cardiac and skeletal muscle. J Clin Invest (2004) 1.23
Deletion of periostin reduces muscular dystrophy and fibrosis in mice by modulating the transforming growth factor-β pathway. Proc Natl Acad Sci U S A (2012) 1.23
Cardiac assessment in duchenne and becker muscular dystrophies. Curr Heart Fail Rep (2010) 1.21
Repairing the tears: dysferlin in muscle membrane repair. Trends Mol Med (2003) 1.21
Genetic compensation for sarcoglycan loss by integrin alpha7beta1 in muscle. J Cell Sci (2004) 1.19
Myoferlin regulates vascular endothelial growth factor receptor-2 stability and function. J Biol Chem (2007) 1.19
Impaired muscle growth and response to insulin-like growth factor 1 in dysferlin-mediated muscular dystrophy. Hum Mol Genet (2010) 1.19
Myostatin blockade improves function but not histopathology in a murine model of limb-girdle muscular dystrophy 2C. Muscle Nerve (2008) 1.17
Smooth muscle cell-extrinsic vascular spasm arises from cardiomyocyte degeneration in sarcoglycan-deficient cardiomyopathy. J Clin Invest (2004) 1.14
Nesprins, but not sun proteins, switch isoforms at the nuclear envelope during muscle development. Dev Dyn (2010) 1.13
Sulfonylurea receptor-dependent and -independent pathways mediate vasodilation induced by ATP-sensitive K+ channel openers. Mol Pharmacol (2008) 1.13
Mice lacking sulfonylurea receptor 2 (SUR2) ATP-sensitive potassium channels are resistant to acute cardiovascular stress. J Mol Cell Cardiol (2007) 1.13
Cardiac sulfonylurea receptor short form-based channels confer a glibenclamide-insensitive KATP activity. J Mol Cell Cardiol (2007) 1.12
Molecular identification and functional characterization of a mitochondrial sulfonylurea receptor 2 splice variant generated by intraexonic splicing. Circ Res (2009) 1.12
SMAD signaling drives heart and muscle dysfunction in a Drosophila model of muscular dystrophy. Hum Mol Genet (2010) 1.10
Genetic manipulation of dysferlin expression in skeletal muscle: novel insights into muscular dystrophy. Am J Pathol (2009) 1.08
Sarcomere mutations in cardiomyopathy with left ventricular hypertrabeculation. Circ Cardiovasc Genet (2009) 1.07
Advocacy: yes we can. J Clin Invest (2012) 1.07
Annexin A6 modifies muscular dystrophy by mediating sarcolemmal repair. Proc Natl Acad Sci U S A (2014) 1.07
TBX5 drives Scn5a expression to regulate cardiac conduction system function. J Clin Invest (2012) 1.06
Endocytic recycling proteins EHD1 and EHD2 interact with fer-1-like-5 (Fer1L5) and mediate myoblast fusion. J Biol Chem (2010) 1.05
Distinct genetic regions modify specific muscle groups in muscular dystrophy. Physiol Genomics (2010) 1.05
Phospholamban R14 deletion results in late-onset, mild, hereditary dilated cardiomyopathy. J Am Coll Cardiol (2006) 1.04
Mechanisms of muscle weakness in muscular dystrophy. J Gen Physiol (2010) 1.03
Emery-Dreifuss muscular dystrophy. Handb Clin Neurol (2011) 1.01
Zeta-sarcoglycan, a novel component of the sarcoglycan complex, is reduced in muscular dystrophy. Hum Mol Genet (2002) 1.01
Processing and assembly of the dystrophin glycoprotein complex. Traffic (2007) 1.01
Genetic disruption of calcineurin improves skeletal muscle pathology and cardiac disease in a mouse model of limb-girdle muscular dystrophy. J Biol Chem (2007) 1.00
Myoferlin is required for insulin-like growth factor response and muscle growth. FASEB J (2009) 0.99
Ferlin proteins in myoblast fusion and muscle growth. Curr Top Dev Biol (2011) 0.98
Hydrogen sulfide dilates cerebral arterioles by activating smooth muscle cell plasma membrane KATP channels. Am J Physiol Heart Circ Physiol (2011) 0.96
Lamin A/C truncation in dilated cardiomyopathy with conduction disease. BMC Med Genet (2003) 0.96
S100A12 expression in thoracic aortic aneurysm is associated with increased risk of dissection and perioperative complications. J Am Coll Cardiol (2012) 0.95
Duchenne muscular dystrophy: how bad is the heart? Heart (2008) 0.95
Modifying muscular dystrophy through transforming growth factor-β. FEBS J (2013) 0.95
Genetic pathways of vascular calcification. Trends Cardiovasc Med (2012) 0.94
Cardiomyopathy is independent of skeletal muscle disease in muscular dystrophy. FASEB J (2002) 0.94
Nuclear sequestration of delta-sarcoglycan disrupts the nuclear localization of lamin A/C and emerin in cardiomyocytes. Hum Mol Genet (2006) 0.93
Exon-skipping therapy: a roadblock, detour, or bump in the road? Sci Transl Med (2014) 0.92
Genetic modifiers of muscular dystrophy: implications for therapy. Biochim Biophys Acta (2006) 0.91
Secondary coronary artery vasospasm promotes cardiomyopathy progression. Am J Pathol (2004) 0.91
The superhealing MRL background improves muscular dystrophy. Skelet Muscle (2012) 0.90
Gene expression, chromosome position and lamin A/C mutations. Nucleus (2011) 0.90
Sarcoglycans in vascular smooth and striated muscle. Trends Cardiovasc Med (2003) 0.88
Myoferlin regulation by NFAT in muscle injury, regeneration and repair. J Cell Sci (2010) 0.87
Impaired exercise tolerance and skeletal muscle myopathy in sulfonylurea receptor-2 mutant mice. Am J Physiol Regul Integr Comp Physiol (2009) 0.87
Modifier genes and their effect on Duchenne muscular dystrophy. Curr Opin Neurol (2015) 0.87
Modifiers of heart and muscle function: where genetics meets physiology. Exp Physiol (2013) 0.86
Sarcomere mutations in cardiomyopathy, noncompaction, and the developing heart. Circulation (2008) 0.86
Long-term survival of transplanted stem cells in immunocompetent mice with muscular dystrophy. Am J Pathol (2008) 0.86
A novel FKRP mutation in congenital muscular dystrophy disrupts the dystrophin glycoprotein complex. Neuromuscul Disord (2007) 0.86
A pilot study of a family history risk assessment tool for cardiovascular disease. J Genet Couns (2008) 0.84
Genetic deletion of NOS3 increases lethal cardiac dysfunction following mouse cardiac arrest. Resuscitation (2010) 0.83
Vasodilation induced by oxygen/glucose deprivation is attenuated in cerebral arteries of SUR2 null mice. Am J Physiol Heart Circ Physiol (2011) 0.83
The mitochondrial bioenergetic phenotype for protection from cardiac ischemia in SUR2 mutant mice. Am J Physiol Heart Circ Physiol (2010) 0.82
Cardiomyocyte sulfonylurea receptor 2-KATP channel mediates cardioprotection and ST segment elevation. Am J Physiol Heart Circ Physiol (2010) 0.81
Reengineering a transmembrane protein to treat muscular dystrophy using exon skipping. J Clin Invest (2015) 0.80
Beta-myosin heavy chain gene mutations in familial hypertrophic cardiomyopathy: the usual suspect? Circ Res (2002) 0.80
The interaction of coronary tone and cardiac fibrosis. Curr Atheroscler Rep (2005) 0.79
The emerging genetic landscape underlying cardiac conduction system function. Birth Defects Res A Clin Mol Teratol (2011) 0.79
Ventricular fibrillation following autologous intramyocardial cell therapy for inherited cardiomyopathy. Cardiovasc Pathol (2008) 0.78
Setting the pace: Tbx3 and Tbx18 in cardiac conduction system development. Circ Res (2009) 0.78
Cardiac magnetic resonance of left ventricular trabeculation: the new normal. Circ Cardiovasc Imaging (2011) 0.78
Cardiomyopathy in Muscular Dystrophy: When to Treat? JAMA Cardiol (2016) 0.78
Regenerating more than muscle in muscular dystrophy. Circulation (2004) 0.77
Dynamin 2 the rescue for centronuclear myopathy. J Clin Invest (2014) 0.77
Hypertrophic cardiomyopathy: exercise and eat right. Circ Res (2006) 0.77
Welcome to the splice age: antisense oligonucleotide-mediated exon skipping gains wider applicability. J Clin Invest (2016) 0.75
Intermittent glucocorticoid steroid dosing enhances muscle repair without eliciting muscle atrophy. J Clin Invest (2017) 0.75
Better living through peptide-conjugated chemistry: next-generation antisense oligonucleotides. J Clin Invest (2019) 0.75